United States Federal Judge Paul G. Cassell granted Hema Metrics' motion for Summary Judgment on the issue of infringement for all inventions. In the ruling, the court concluded that Hema
StemCells, Inc. has announced that the Company has been issued U.S. patent 6,777,233 for work done at the Company covering composition of matter claims for the human neural stem cell."Thi
Body tissues such as blood vessels, cartilage and skin - even whole organs such as kidneys, livers and hearts - could become more widely available for transplants as a result of a patent issued recently to Organ Recovery Systems of Chicago for a method
FMD has announced it has been granted patent 6,780,161. Issued on August 24, 2004, the patent covers the new technology of Twinheads(R) which uses two or more shock wave sources in the extracorp
Dangerous multi-drug-resistant bacteria are also developing immunity to hospital disinfectants and antiseptics, according to new research presented today at the Society for General Microbiology's 155th
NMT Medical today announced a favorable decision by the U.S. Patent and Trademark Office Board of Appeals relating to the Company's patent infringement actions against AGA Medical Corp.In D
The U.S. Patent and Trademark Office has issued the University of Utah U.S. patent No. U.S. 6,787,338 (the '338 patent) relating to methods of rapid nucleic acid amplification. The issuance of th
The physician who revolutionized screening methods for glaucoma nearly 20 years ago has patented a new device aimed at detecting glaucoma, a leading cause of blindness. Steven Feldon, M.D., director of the Eye Institute at the
Chiron Corporation has announced that it has reached a settlement with F. Hoffmann-La Roche (Roche) in a dispute over licensing fees and royalties that Chiron had asserted was owed to the company under
Scientists from MitoChroma Research have recently announced a patent pending discovery that could complement current medical management modalities for Type 2 Diabetes, insulin resistance and the se
Date: Monday, 10-Jul-2006
Ryogen and R&D Systems have announced that they have entered into a nonexclusive license agreement whereby RDSI has licensed from Ryogen the patent directed to the clinically important Aminopeptidase P gene.The US Patent No. 6,399,349 titled "Human Aminopeptidase P Gene," which is the subject of the License Agreement, covers the XPNPEP2 gene that codes for the clinically important protein, membrane-bound aminopeptidase P (AmP) discovered by Dr. James Ryan in the sixties. Dr. Ryan subsequently sequenced the XPNPEP2 gene that codes for the AmP. This gene is a significant marker for hypertension, angioedema, rejection of kidney transplants, certain tumors and other diseases. This valuable patent covers the cDNA and gDNA sequences encoding AmP, a method of producing recombinant AmP, diagnostics for detecting AmP abnormalities, and prevention and treatment of medical conditions, associated with the mutation of the AmP gene.
"We are happy to extend a license under the AmP Patent to R&D Systems," said Valeria Poltorak, Ryogen's Vice President. "We look forward to working with RDSI to bring this important gene to the research community," she concluded.
"We are pleased to take a license under the AmP patent," said Dr. Paige Jensen, RDSI's Associate General Counsel. "As a leading provider of research reagents, we will be making recombinant Aminopeptidase P protein available for research applications to academic and research institutions."
Dr. James Ryan, the inventor of the '349 patent and the Chief Scientist of Ryogen stated that he was delighted to see R&D Systems' interest in his discovery. He believes that the availability of research reagents will help his discovery make its way to diagnostic and therapeutic applications.
http://www.ryogen.com